IGM MONOCLONAL GAMMOPATHY

Clinical trials for IGM MONOCLONAL GAMMOPATHY explained in plain language.

Never miss a new study

Get alerted when new IGM MONOCLONAL GAMMOPATHY trials appear

Sign up with your email to follow new studies for IGM MONOCLONAL GAMMOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Gut bacteria drug shows promise against blood disorder

Disease control Completed

This early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…

Matched conditions: IGM MONOCLONAL GAMMOPATHY

Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control

Last updated Jun 10, 2026 13:25 UTC

IGM MONOCLONAL GAMMOPATHY

Get alerted when new IGM MONOCLONAL GAMMOPATHY trials appear

Gut bacteria drug shows promise against blood disorder